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Abstract
Background: Opportunistic infections are relatively rare in early human immunodeficiency virus infection, especially
infection with Mycobacterium tuberculosis. Here, we report a patient who presented with acute human immunodeficiency
virus and multidrug-resistant M. tuberculosis co-infections.
Case presentation: A 27-year-old homosexual male was admitted for fever, cough, and hepatitis. At the time
of admission, the p24 antigen was detected in his serum, indicating that he had an acute human immunodeficiency
virus infection. He was also diagnosed with disseminated tuberculosis spreading to the lung and skin. Anti-tuberculosis
medication had been started earlier with one-week intervals of highly active antiretroviral therapy. Despite prolonged
anti-tuberculosis treatment, the patient developed tuberculous meningitis on the 50th day of admission.
Multidrug-resistant tuberculosis was cultured from his sputum and cerebrospinal fluid. The patient was
successfully treated with second line anti-tuberculosis medication and antiretroviral treatment.
Conclusion: This is the first case of acute human immunodeficiency virus and multi drug-resistance tuberculosis
co-infections. This case indicates that tuberculosis infection should be considered even in patients with acute
human immunodeficiency virus infection.
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Background
Although M. tuberculosis (TB) is the major opportunis-
tic infection in human immunodeficiency virus (HIV)-
infected patients, conjunction with acute HIV infection
is very rare. The only one case of TB infection during
the acute HIV infection was reported [1]. multi drug-
resistance (MDR)-TB in acute HIV infection has not been
reported previously to our knowledge.
We describe a case of subsequent dissemination of
MDR-TB to the lung, skin and central nervous system
(CNS) in a patient with acute HIV infection. The
patient was successfully treated with second-line anti-
TB medication with the use of antiretroviral therapy
(ART).
Case presentation
A 27-year-old homosexual male was admitted for fever,
cough and nausea lasting for 2 weeks. He had no history
of underlying disease. He had unprotected homosexual
contact with multiple partners several weeks prior to
presentation. Initial physical examination revealed a
temperature of 37.5°C, otherwise stable. His total white
blood cell count was 1800 cells/mm3, with hemoglobin
level and platelet count of 15.7 g/dl and 380,000/mm3.
Serum aspartate transaminase and alanine aminotransferase
was 199 IU/mL and 191 IU/mL. Chest x-ray showed no
active lung lesions.
On the fifth day of admission, the patient developed fever
with a body temperature of 40.0°C, whole body skin rash
and cough. A fourth-generation screening HIV test for the
detection of p24 antigen and HIV 1/2 antibodies (Abbott
Molecular inc., Chicago, Illinois) was positive, although it
had been negative when he was checked 6 months prior to
presentation. Chest Computed Tomography scan showed
hematogenous spreading pulmonary nodules. We per-
formed a skin punch biopsy of the rash on the patient’s
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left shoulder. AFB staining of the skin specimen showed
multiple positive bacilli, which was suggestive of mycobac-
terial infection on the skin (Figure 1). Additional tests of
the skin tissue were positive for M. tuberculosis by poly-
merase chain reaction (PCR). Furthermore, TB-PCR was
also positive in sputum. On hospital day 14, we started the
patient on anti-TB medication including isoniazide, rifam-
picin, ethambutol, and pyrazinamide. During that period
of time, Western Blot results for HIV were positive in the
gp160 and p24 bands. Measurements of HIV-1 RNA
plasma levels by quantitative real-time PCR (COBAS
TaqMan® HIV-1 Test, Roche Diagnostics, Mannheim,
Germany) were greater than 10,000,000 copies/ml.
CD4 T-cell counts at the same time were 55 cells/μL.
The CD4 cells accounted for 33.5% of lymphocytes.
The ratio of CD4/CD8 was 0.55.
Despite anti-TB treatment, the patient’s condition de-
teriorated, with ongoing fever and confused mental state.
On hospital day 18, after four days of anti-TB treatment,
he presented with lethargic state and cardiopulmonary
instability with systolic blood pressure of 78 mmHg, and
oxygen saturation level of 87% on reservoir mask. He
was transferred to the intensive care unit (ICU). Follow-
up chest CT showed aggravated hematogenous spread-
ing nodules. The cerebrospinal fluid (CSF) was sterile.
The growth of bacteria including M. tuberculosis was
not observed in blood, sputum and urine cultures. Sero-
logic tests for toxoplasma, cytomegalovirus, herpes simplex
virus and Epstein-Barr virus were all negative.
On the 21st day after admission, we started ART with
efavirenz, lamivudine, and abacavir within 2 weeks of
anti-TB therapy, because he had CD4 T-cell counts
around 50 cells/μL and severe organ dysfunction (http://
aidsinfo.nih.gov/guidelines).
The HIV-1 RNA viral load at this time was decreased to
724 copies/mL, but CD4+ T cell counts remained low, 45
cells/μL. Growth of M. tuberculosis in sputum was ob-
served. Rapid molecular testing to detect drug-resistant
tuberculosis (Genotype® MTBDRplus, Hain Lifescience
GmbH, Nehren, Germany) revealed isoniazid-resistance
and rifampin-susceptibility. Levofloxacin and amikacin
were added to the first line anti-TB medication. After
20 days of ICU care, the patient was transferred to the
general ward.
On the 50th day of admission, the patient’s body
temperature increased to 39.7°C. Lumbar puncture was
performed due to newly developed severe headache
and vomiting. CSF analysis showed that leukocytes
were 1,258/mm3 with 94% poly-dominant cells. An M.
tuberculosis PCR test of the CSF fluid was positive.
Due to concerns regarding treatment failure of the
anti-TB medication and the development of immune
reconstitution inflammatory syndrome (IRIS), the
anti-TB regimen was modified to include cycloserin,
prothionamide, levofloxacin, rifabutin and amikacin
and dexamethasone was added for the management of
IRIS.
After 80 days of admission, drug susceptibility testing
of sputum TB indicated MDR-TB that showed resistance
to isoniazid, rifampicin and quinolone and sensitivity to
rifabutin, ethambutol, pyrazinamide, amikacin, cyclo-
serin, prothionamide and kanamycin. Drug susceptibility
test (DST) was performed using the conventional abso-
lute concentration method with Löwenstein-Jensen
medium at the Korean Institute of Tuberculosis, the
supranational reference laboratory for mycobacterial
culture and DSTs [2]. Antimicrobial susceptibility tests
were performed by the recommendations of the Clin-
ical and Laboratory Standards Institute [3]. The results
of susceptibility tests in sputum led us to re-modify the
patient’s anti-TB medication regimen to rifabutin,
ethambutol, pyrazinamide, PAS, cycloserin, prothionamide
and kanamycin. After 30 days of anti-TB treatment with re-
modified regimens, the additional resistance to ethambutol
and pyrazinamide for TB was reported in the result of
tuberuclosis DST in CSF, compared to that in sputum. We
subsequently added amoxicillin-clavulanate and excluded
ethambutol and pyrazinamide after DST result of CSF was
identified.
Finally, 120 days after admission, 40 days since the re-
modified TB medication was started according to DST
results in sputum, the patient had recovered and exhib-
ited no fever. Chest X-ray revealed near complete regres-
sion of infiltration, and follow-up sputum AFB culture
was negative. CSF analysis showed sterile findings. The
patient was subsequently discharged from the hospital.
Five months after having started ART medication, his
HIV RNA load was declined to 22 copies/mL and his
CD4 count had increased to 510 cells/μL. At the time
of writing, the patient was maintaining his anti-TB
Figure 1 Acid fast stain on section of skin lesion reveals
scattered positive bacilli (inlet) (AFB stain x400).
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medications with prothionamide, cycloserine, amoxicillin-
clavulanate, PAS and kanamycin and ART medication with
lamivudine, abacavir, and efavirenz.
Conclusions
Acute/early HIV infection is referred to as primary HIV
infection or seroconversion illness. Patients observed at
the time of seroconversion have been found to present
with symptoms ranging from flu-like illness to encephalop-
athy, 2–3 weeks after acquisition of virus. Most symptoms
usually resolve spontaneously. In the seroconversion state,
there is sometimes a high rate of viral replication, leading
to a rise in HIV viral load, and concomitant immune-
suppression due to rapid loss of CD4+ T cells [4]. Op-
portunistic infections rarely occur in acute HIV infected
patients who are in a transient CD4+ lymphocytopenia
state. Esophageal candidiasis, toxoplasmic encephalitis,
Pneumocystis jirovecii pneumonia, and cytomegaloviral
disease have previously been reported [5-11].
In contrast to other HIV-associated opportunistic in-
fections, TB can occur in HIV-infected patients at any
level of immunodeficiency, regardless of CD4+ T cell
counts. However, TB rarely occurs in acute HIV infec-
tion with only one case active pulmonary TB during
acute HIV infection previously reported in the literature
[1]. In our case, the patient suffered from flu-like symp-
toms and also exhibited the clinical findings of acute
HIV infection. His HIV-1 RNA viral load, which is the
most sensitive marker for acute HIV infection, was
markedly elevated, while an HIV antigen/antibody test
had been negative which had been tested 6 months
prior. His Western Blot results for the HIV test were
only positive in the gp160 and p24 bands, indicating that
our patient suffered from acute HIV infection rather
than latent AIDS.
In this case, DST for TB in sputum revealed the pa-
tient was infected with an MDR pathogen 80 days after
admission. DST was performed by conventional absolute
concentration method in Löwenstein-Jensen media at
the Korean Institute of Tuberculosis. The conventional
DST method usually took longer than two months to
execute [12], so it could prolong the diagnosis and treat-
ment of MDR pathogen. Recently, rapid direct suscepti-
bility tests such as Genotype MTBDRplus assay were
found to be useful to detect MDR-TB earlier [13]. Inter-
estingly, additional resistance to ethambutol and pyrazi-
namide of TB was detected in DST result from CSF,
which was acquired after 30 days of anti-TB medication.
The acquisition of additional resistance during treatment
might be associated with baseline resistance to 1st-line
drugs, higher degree of lung pathology, and HIV co-
infection [14]. In addition, it might be due to genomic
evolution of serial clinical strains in patient under ther-
apy. Recent studies applying genome sequencing tests
revealed the mixture of different subpopulations and the
stepwise acquisition of resistance conferring mutations
selecting for the most resistant phenotype in the same
patients [15,16].
In this case, drug susceptibility tests of TB in sputum
and CSF revealed the patient was infected with an MDR
pathogen. To the best of our knowledge, this is the first
case of acute HIV and MDR-TB co-infections. MDR-TB
is caused by strains of M. tuberculosis that are resistant
to isoniazid and rifampicin, with or without resistance to
other anti tuberculous agents. As a result, this form of
the disease is more difficult to treat than ordinary TB
and requires up to 2 years of multidrug treatment. The
relationship between MDR-TB and HIV is not yet clearly
understood, but many studies have found strongly in-
creased risks for MDR-TB among patients co-infected
with HIV [17,18]. A recent systemic review and meta-
analysis showed that HIV significantly increases the risk
of MDR TB. HIV/MDR TB co-infection has been associ-
ated with high mortality rates due to greater degrees of
immunosuppression and treatment failure [19]. CNS/
meningeal involvement of TB in HIV-infected patients
is usually observed in AIDS-defining condition [20].
Disseminated military MDR-TB with cutaneous and
meningeal expressions, during acute stage of HIV
infection in this case, might be attributed to his low
CD4+ cell counts.
Both TB and HIV have profound effects on the im-
mune system, but the mechanisms behind the break-
down of the immune defense of associated with co-
infection are not fully understood. HIV infection inter-
feres with generation of effector memory CD4+ T cells
that migrate to the lung (the primary site of M. TB in-
fection), and M. TB specific CD4+ T-cell responses are
selectively depleted, further reducing the immune sys-
tem’s ability to control TB [17,21]. Other reports also
showed that most opportunistic infections co-existing
acute HIV infection occurred when CD4+ T cell counts
temporarily dropped [6,8,22]. Moreover, the granuloma
formation, which prevents the spread of TB, may fail in
HIV-infected patients, probably due to the deaths of
CD4+ T cells in the granuloma resulting in disruption of
granuloma structure [17,20]. In our case, the patient’s
initial CD4+ T cell counts were 55 cells/μL; this deple-
tion of M. TB specific CD4+ T cells may contribute to
reduced immune-response for tuberculosis in the lung.
Furthermore, lack of the granuloma formation due to re-
duced T cell-response may result in subsequent dissem-
ination form the lung to the skin and CNS. In this case,
however, it is difficult to distinguish whether dissemination
of TB occurred as a result of primary infection or reactiva-
tion of latent infection during the acute HIV infection stage.
The reactivation of latent TB could be suggested as another
possible contributor to the development of TB [23].
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Especially during acute HIV infection, regulatory T cells
(Tregs) are upregulated, but HIV can target CD4+ Treg
cells for infection, and Treg cells can suppress ant-HIV im-
munity, which may together promote an increase in acute
viremia and infected cells [24]. High levels of Treg as well
as numerical deficit of CD4+ T cells during acute phase of
HIV infection imply immune dysregulation and this may
have favoured the reactivation of latent TB [1].
In conclusions, we described a patient with both acute
HIV infection and MDR-TB disseminated infection. The
patient suffered from a life-threatening course while in
the hospital, but was ultimately treated successfully with
ART and second line anti-TB medications. This case em-
phasizes the fact that physicians must be aware that ser-
ious opportunistic infections including MDR-TB can
occur during the acute phase of HIV infection.
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